Venture Report: Third Arc’s $165M series A; Brenig heads for clinic with $65M round

Two start-ups are moving toward the clinic with new venture rounds announced this week. One is advancing programs for cancer and immune conditions, and the other for Parkinson’s disease.

Two-year-old Third Arc Bio Inc. is preparing to enter the clinic with a $165 million series A round. Backed initially by Omega Funds during its seed stage, Third Arc has assembled a syndicate led by Vida Ventures alongside Cormorant Asset Management and Hillhouse Investment for the round...